Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 50,100 | 19,728,681 | 19,649,601 | 14,419,687 | 52,034,400 | 105,882,469 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 50,100 | 19,728,681 | 19,649,601 | 14,419,687 | 52,034,400 | 105,882,469 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 40,777,150 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 65,105,319 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 50,100 | 19,728,681 | 19,649,601 | 14,419,687 | 52,034,400 | 105,882,469 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 115 | 24,896 | 83,412 | 556,550 | 664,973 | |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | |||||
| 11 | Total support Add lines 7 through 10. | 106,613,927 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e | Discount claimed for blockage or other factors (explain in detail in Part VI): | |||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| 7 | Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions) | |||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2014 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2014 |
(iii) Distributable Amount for 2014 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2014 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2014 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2014: | ||||
| a From 2009.......X | ||||
| b From 2010.......X | ||||
| c From 2011.......X | ||||
| d From 2012.......X | ||||
| e From 2013....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2014 distributable amount | ||||
|
i
Carryover from 2009 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2014 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2014 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2014, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2014. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2015. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a From 2010.......X | ||||
| b From 2011.......X | ||||
| c From 2012.......X | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| The Organization's Mission | Form 990, Part I, Line 1 & Part III, Line 1: NEW YORK GENOME CENTER, INC. IS ORGANIZED AND SHALL BE OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION BY LEADING ACADEMIC, MEDICAL, AND RESEARCH INSTITUTIONS FOR THE PURPOSE OF ESTABLISHING A STATE-OF-THE- ART, WORLD CLASS GENOME SEQUENCING, BIOINFORMATICS AND RESEARCH CENTER IN NEW YORK CITY, WITH THE FOLLOWING KEY OBJECTIVES: (I) CREATING AN INTELLECTUALLY VIBRANT COLLABORATION AMONGST THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY; (II) RECRUITING WORLD CLASS SCIENTIFIC LEADERSHIP TO DIRECT THE SCIENTIFIC DEVELOPMENT OF THE CORPORATION, TOGETHER WITH THE MEMBERS OF THE CORPORATION; (III) OBTAINING COMMITMENTS FROM THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO AFFILIATE WITH AND USE SERVICES PROVIDED BY THE CORPORATION; (IV) PROVIDING SEQUENCING AND BIOINFORMATICS SERVICES TO THE ACADEMIC AND SCIENTIFIC COMMUNITIES, INCLUDING THE INSTITUTIONAL FOUNDING MEMBERS; (V) DEVELOPING ADVANCED BIOINFORMATICS CAPABILITIES BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE CORPORATION'S FACILITIES; (VI) ADVANCING THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS TO TREAT HUMAN DISEASE; AND (VII) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. |
| PROGRAM SERVICE ACCOMPLISHMENT - SEQUENCING | FORM 990, PART III, LINE 4A: THE NEW YORK GENOME CENTER, INC. STARTED ITS RESEARCH SEQUENCING SERVICES IN 2012 WITH FIVE SEQUENCING MACHINES IN A TEMPORARY PILOT LAB SPACE. IN 2013, THE CENTER OPENED ITS HEADQUARTERS AT 101 AVENUE OF THE AMERICAS IN NEW YORK CITY. THE NEW FACILITY INCLUDES: 30,000 SQUARE FEET OF SEQUENCING LAB SPACE; THIS IS MORE SEQUENCING CAPACITY THAN ANY OTHER SINGLE INSTITUTION IN THE CITY AND SERVES AS A STATE OF THE ART SEQUENCING CENTER TO THE ACADEMIC AND SCIENTIFIC COMMUNITIES IN NEW YORK CITY TO AID THEM IN RESEARCH, INCLUDING COLLABORATIVE RESEARCH WITH THE CENTER, TO ADVANCE THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES, AND THERAPUTICS TO TREAT HUMAN DISEASE A DEDICATED OPEN-PLAN BIOINFORMATICS FLOOR TO ENCOURAGE DISCUSSION AND COLLABORATION AMONG RESEARCHERS AND SCIENTISTS A DATA STORAGE ANNEX TO SAFELY STORE THE IMMENSE AMOUNTS OF DATA PRODUCED AND FACILITATE RESEARCH STUDIES ACROSS A LARGE NUMBER OF PEOPLE TRANSLATIONAL RESEARCH LABS WITH SPACE TO HOST A NUMBER OF PRINCIPAL INVESTIGATORS AND THEIR TEAMS FROM VARIOUS MEMBER INSTITUTIONS AN INNOVATION LAB TO TEST AND EVALUATE NEW SEQUENCING TECHNOLOGIES A CLIA LAB (APPLICATION PENDING) TO SERVICE CLINICAL LABORATORY TESTING NEEDS In 2014, purchased the Illumina HiSeq X ten system. NYGC is the only institution in the Tri-State Area to acquire the HiSeq X Ten, the fastest and most advanced sequencing technology available. At December 31, 2014, NYGC's facility contained 10 Illumina HiSeq X instruments to enable sequencing of up to 18,000 30x human whole genomes or 4,500 tumor/normal pairs at 80x/40x each year, and 12 Illumina HiSeq 2500s to allow annual sequencing of tens of thousands of whole exome, RNA, methylation, or custom samples. SEQUENCING IS A LABORATORY PROCESS THAT DETERMINES THE COMPLETE DNA SEQUENCE OF AN ORGANISM'S GENOME AT A SINGLE TIME. A SINGLE HUMAN GENOME YIELDS APPROXIMATELY 750 KILOBYTES OF DATA. THIS DATA IS THEN PUT THROUGH A COMPUTATION ANALYSIS TO GENERATE BIOINFORMATICS ACCORDING TO THE RESEARCHER'S SPECIFICATIONS. BIOINFORMATICS IS A BRANCH OF BIOLOGICAL SCIENCE WHICH DEALS WITH ANALYZING BIOLOGICAL DATA AND EXPRESSING IT GRAPHICALLY USING SPECIALIZED SOFTWARE AND COMPUTATIONAL METHODS. THROUGH BIOINFORMATICS, GENOMIC VARIATIONS CAN BE DETECTED AND ANALYZED. IN HUMANS, GENETIC VARIATION CAN HAVE MEDICAL CONSEQUENCES AFFECTING DISEASE SUSCEPTIBILITY, INCLUDING PREDISPOSITION TO COMPLEX GENETIC DISEASES SUCH AS CANCER, DIABETES, CARDIOVASCULAR DISEASE, AND ALZHEIMER'S DISEASE. THEY CAN ALSO IMPACT AN INDIVIDUAL'S RESPONSE TO CERTAIN DRUG TREATMENTS, CAUSING THEM TO RESPOND WELL, NOT RESPOND AT ALL, OR EXPERIENCE ADVERSE SIDE EFFECTS. PROGRAM SERVICE ACCOMPLISHMENT - RESEARCH FORM 990, PART III, LINE 4C: New York Genome Center conducts innovative research and methods development and improvement. Several key areas of disease focus include cancer, autoimmune disease and neurological disorders. In support of the latter, NYGC's Center for Genomics of Neurodegenerative Disease (CGND) is dedicated to studying neurodegenerative diseases such as ALS and Alzheimer's. The CGND's partners include our IFMs, the Perelman School of Medicine at the University of Pennsylvania, the Northeast ALS Consortium, Mass General Hospital/Harvard Medical School and UMass Medical School. In addition to the CGND, NYGC has initiated several collaborative clinical studies, including those focused on rheumatoid arthritis and pediatric leukemia and neuroblastoma. NYGC also launched a multiinstitutional trial in which we are partnering with IBM to explore whether their Watson artificial intelligence technology can help create personalized treatments for patients with glioblastoma, a deadly form of brain cancer. NYGC's faculty members, who each hold a joint appointment at a Member Institution, are leading complementary research in areas including schizophrenia, population genomics, evolutionary mechanisms and disease risk, single cell genomics, and more. NYGC also has an Innovation Lab dedicated to protocol development, equipment evaluation, and informatics tool development and integration. |
| SIGNIFICANT CHANGE TO GOVERNING DOCUMENTS | FORM 990, PART VI, SECTION A, LINE 4: IN 2014, THE ORGANIZATION'S BYLAWS WERE AMENDED. The changes included expanded decision making for the IFM directors requiring 2/3 vote, increase from 10 to 17 of non-IFM directors, and elimination of the executive committee. |
| ORGANIZATION MEMBERS | FORM 990, PART VI, SECTION A, LINE 6: THERE ARE FOUR (4) CATEGORIES OF MEMBERS OF THE CENTER: INSTITUTIONAL FOUNDING MEMBERS, ASSOCIATE MEMBERS, PHARMA/TECHNOLOGY MEMBERS AND OTHER MEMBERS. *THE INSTITUTIONAL FOUNDING MEMBERS OF THE CENTER ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICAL COLLEGE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) MOUNT SINAI SCHOOL OF MEDICINE, (6) NEW YORK-PRESBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, (8) NORTH SHORE LONG ISLAND JEWISH HEALTH SYSTEM, (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) Albert Einstein School of Medicine of Yeshiva University *ASSOCIATE MEMBERS: (1) American Museum of Natural History (2) Hospital for Special Surgery (3) The New York Stem Cell Foundation (4) Roswell Park Cancer Institute *PHARMACEUTICAL/TECHNOLOGY MEMBERS: (1) International Business Machines (IBM) *OTHER MEMBERS - NONE |
| ORGANIZATION MEMBERS - DECISION MAKING | FORM 990, PART VI, SECTION A, LINE 7A & 7B: EACH INSTITUTIONAL FOUNDING MEMBER WILL APPOINT ONE REPRESENTATIVE TO SERVE ON THE BOARD OF DIRECTORS. THE EXECUTIVE DIRECTOR ALSO SERVES ON THE BOARD. MANAGEMENT OBTAINS APPROVAL FROM THE BOARD PRIOR TO MAKING OPERATIONAL DECISIONS, INCLUDING APPROVAL OF THE OPERATING BUDGET, CERTAIN HIRING AND TERMINATION MATTERS, ETC. |
| FORM 990 REVIEW | FORM 990, PART VI, SECTION B, LINE 11: THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT 990, MANAGEMENT (VP OF FINANCE, Chief of Staff, AND PRESIDENT) WILL REVIEW THE 990. MANAGEMENT WILL THEN PRESENT THE 990 TO THE FINANCE AND AUDIT COMMITTEE. AFTER ALL COMMENTS AND REVISIONS ARE ADDRESSED, THE FINANCE AND AUDIT COMMITTEE AND NYGC EXECUTIVE TEAM WILL RECOMMEND THE BOARD OF DIRECTORS TO APPROVE THE 990. THE BOARD OF DIRECTORS WILL THEN REVIEW AND APPROVE THE FINAL 990. |
| CONFLICT OF INTEREST POLICY & REVIEW | FORM 990, PART VI, SECTION B, LINE 12C: THE CENTER REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, PRINCIPAL OFFICERS, OR MEMBERS OF A COMMITTEE IN WHICH THE BOARD HAS DELEGATED POWERS) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. ADDITIONALLY, OTHER INDIVIDUALS LISTED ON THE FORM 990 COMPLETE THE QUESTIONNAIRE. THE CENTER FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY, COMMENCING WITH DECEMBER 2013. IF An interested person HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE may make a presentation at the board or committee meeting, but after such presentation, he/she shall leave the meeting during the discussion of, and the vote on, the transaction or arrangement that results in the conflict of interest. |
| WHISTLEBLOWER POLICY | FORM 990, PART VI, SECTION B, LINE 13: THE ORGANIZATION'S GOVERNING BODY ADOPTED A WRITTEN WHISTLEBLOWER POLICY IN 2015. DOCUMENT RETENTION AND DESTRUCTION POLICY FORM 990, PART VI, SECTION B, LINE 14: THE ORGANIZATION'S GOVERNING BODY ADOPTED A WRITTEN DOCUMENT RETENTION AND DESTRUCTION POLICY IN 2014. |
| COMPENSATION REVIEW | FORM 990, PART VI, SECTION B, LINE 15: NYGC bases SALARIES ON MARKET SURVEYS. IN 2012, THE INDEPENDENT BOARD APPROVED BOB DARNELL'S COMPENSATION; THE BOARD ALSO WORKED CLOSELY WITH THE PRESIDENT AND A THIRD PARTY RECRUITING FIRM TO DETERMINE SENIOR MANAGEMENT COMPENSATION. When determining the salary amount for top management positions, NYGC utilizes an independent third-party provider for compensation data (e.g. Radford). NYGC also obtains compensation data for similar positions at similar sized not-for-profit companies, in the relevant field (from 990s). If other documentation is available during the time when salary is determined, NYGC will include for consideration (e.g. other offers). In 2014, NYGC established an INDEPENDENT Executive Compensation Committee. Utilizing comparability data, the compensation committee reviewed salaries of all members of the senior management team, AND SUCH REVIEW WAS DOCUMENTED. |
| DOCUMENT DISCLOSURE | FORM 990, PART VI, SECTION C, LINE 19: THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
| OTHER CHANGE IN NET ASSETS | FORM 990, PART XI, LINE 9: New York State Urban Development Corporation COMMITMENT FEE $ (558,737) |
| Software ID: | |
| Software Version: |